Literature DB >> 17163812

Initiation and progression of atherosclerosis--enzymatic or oxidative modification of low-density lipoprotein?

Michael Torzewski1, Karl J Lackner.   

Abstract

Atherosclerosis is widely regarded as a chronic inflammatory disease that develops as a consequence of entrapment of low-density lipoprotein (LDL) in the arterial intima. Native LDL lacks inflammatory properties, so the lipoprotein must undergo biochemical alterations to become atherogenic. Among several other candidates, two different concepts of lipoprotein modification are propagated, the widespread oxidation hypothesis and the less common E-LDL hypothesis, which proposes that modification of LDL occurs through the action of ubiquitous hydrolytic enzymes (enzymatically modified LDL or E-LDL) rather than oxidation. By clearly distinguishing between the initiation and progression of atherosclerotic lesion development, this article reviews comparative studies of both types of lipoprotein modification and submits a viewpoint for discussion proposing that these lipoprotein modifications do not really compete, but rather complement one another. According to this concept, E-LDL might be more important for the initiation of atherosclerosis, while oxidative modification of LDL might be more helpful for diagnosis and prognosis of the disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17163812     DOI: 10.1515/CCLM.2006.259

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  7 in total

Review 1.  Use of Primary Macrophages for Searching Novel Immunocorrectors.

Authors:  Nikita G Nikiforov; Natalia V Elizova; Michael Bukrinsky; Larisa Dubrovsky; Vsevolod J Makeev; Yoshiyuki Wakabayashi; Poching Liu; Kathy K Foxx; Howard S Kruth; Xueting Jin; Emile R Zakiev; Alexander N Orekhov
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

2.  LDL protein nitration: implication for LDL protein unfolding.

Authors:  Ryan T Hamilton; Liana Asatryan; Jon T Nilsen; Jose M Isas; Timothy K Gallaher; Tatsuya Sawamura; Tzung K Hsiai
Journal:  Arch Biochem Biophys       Date:  2008-08-07       Impact factor: 4.013

3.  Enzymatically modified low-density lipoprotein is recognized by c1q and activates the classical complement pathway.

Authors:  Gérard J Arlaud; Adrienn Biro; Wai Li Ling
Journal:  J Lipids       Date:  2011-03-09

4.  Cardiovascular Complications in CKD Patients: Role of Oxidative Stress.

Authors:  Elvira O Gosmanova; Ngoc-Anh Le
Journal:  Cardiol Res Pract       Date:  2011-01-02       Impact factor: 1.866

Review 5.  Lysosomal acid lipase: at the crossroads of normal and atherogenic cholesterol metabolism.

Authors:  Joshua A Dubland; Gordon A Francis
Journal:  Front Cell Dev Biol       Date:  2015-02-02

6.  Enzymatically Modified Low-Density Lipoprotein Is Present in All Stages of Aortic Valve Sclerosis: Implications for Pathogenesis of the Disease.

Authors:  Laura Twardowski; Fei Cheng; Jens Michaelsen; Stefan Winter; Ute Hofmann; Elke Schaeffeler; Simon Müller; Maike Sonnenberg; Kristin Steuer; German Ott; Matthias Schwab; Ulrich F W Franke; Michael Torzewski
Journal:  J Am Heart Assoc       Date:  2015-10-16       Impact factor: 5.501

7.  Enzyme-modified non-oxidized LDL (ELDL) induces human coronary artery smooth muscle cell transformation to a migratory and osteoblast-like phenotype.

Authors:  Bijoy Chellan; Elizabeth Rojas; Chunling Zhang; Marion A Hofmann Bowman
Journal:  Sci Rep       Date:  2018-08-10       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.